Investigation of Griffithsin's interactions with human cells confirms its outstanding safety and efficacy profile as a microbicide candidate

PLoS ONE

Volumn 6, Issue 8, 2011, Pages

  Kouokam, Joseph Calvin ^a   Huskens, Dana ^b   Schols, Dominique ^b   Johannemann, Andrew ^a   Riedell, Shonna K ^a   Walter, Wendye ^a   Walker, Janice M ^a   Matoba, Nobuyuki ^a   O'Keefe, Barry R ^c   Palmer, Kenneth E ^a  

^a University of Louisville School of Medicine   (United States)

^b REGA INSTITUTE FOR MEDICAL RESEARCH   (Belgium)

^c NATIONAL CANCER INSTITUTE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CONCANAVALIN A; CYANOVIRIN N; GRIFFITHSIN; LECTIN; UNCLASSIFIED DRUG; ALGAL PROTEIN; ANTIINFECTIVE AGENT; CHEMOKINE; CYTOKINE; GRIFFITHSIN PROTEIN, GRIFFITHSIA;

ADULT; ANTIVIRAL ACTIVITY; ARTICLE; CELL INTERACTION; CELL VIABILITY; CYTOKINE RELEASE; DRUG BINDING; DRUG CYTOTOXICITY; DRUG EFFICACY; DRUG SAFETY; EPITHELIUM CELL; FEMALE; GENE EXPRESSION PROFILING; GENE EXPRESSION REGULATION; HUMAN; HUMAN CELL; HUMAN TISSUE; MICROARRAY ANALYSIS; PERIPHERAL BLOOD MONONUCLEAR CELL; T LYMPHOCYTE ACTIVATION; UPREGULATION; UTERINE CERVIX; CELL PROLIFERATION; CYTOLOGY; DRUG EFFECT; FLOW CYTOMETRY; FLUORESCENCE MICROSCOPY; IMMUNOLOGY; LYMPHOCYTE ACTIVATION; METABOLISM; T LYMPHOCYTE; VAGINA; VALIDATION STUDY;

ALGAE;

ADULT; ALGAL PROTEINS; ANTI-INFECTIVE AGENTS; CELL PROLIFERATION; CERVIX UTERI; CHEMOKINES; CYTOKINES; FEMALE; FLOW CYTOMETRY; HUMANS; LECTINS; LYMPHOCYTE ACTIVATION; MICROSCOPY, FLUORESCENCE; T-LYMPHOCYTES; VAGINA;

EID: 79960990935     PISSN: None     EISSN: 19326203     Source Type: Journal    
DOI: 10.1371/journal.pone.0022635     Document Type: Article

References (48)

1. Wei X, Decker JM, Wang S, Hui H, Kappes JC, et al. (2003) Antibody neutralization and escape by HIV-1. Nature 422: 307-312.
2. Shan M, Klasse PJ, Banerjee K, Dey AK, Iyer SP, et al. (2007) HIV-1 gp120 mannoses induce immunosuppressive responses from dendritic cells. PLoS Pathog 3: e169.
3. Doores KJ, Bonomelli C, Harvey DJ, Vasiljevic S, Dwek RA, et al. (2010) Envelope glycans of immunodeficiency virions are almost entirely oligomannose antigens. Proc Natl Acad Sci U S A 107: 13800-13805.
4. Rudd PM, Dwek RA, (1997) Glycosylation: heterogeneity and the 3D structure of proteins. Crit Rev Biochem Mol Biol 32: 1-100.
5. Scanlan CN, Offer J, Zitzmann N, Dwek RA, (2007) Exploiting the defensive sugars of HIV-1 for drug and vaccine design. Nature 446: 1038-1045.
6. Knezevic A, Polasek O, Gornik O, Rudan I, Campbell H, et al. (2009) Variability, heritability and environmental determinants of human plasma N-glycome. J Proteome Res 8: 694-701.
7. Chu CS, Ninonuevo MR, Clowers BH, Perkins PD, An HJ, et al. (2009) Profile of native N-linked glycan structures from human serum using high performance liquid chromatography on a microfluidic chip and time-of-flight mass spectrometry. Proteomics 9: 1939-1951.
8. Francois KO, Balzarini J, (2010) Potential of carbohydrate-binding agents as therapeutics against enveloped viruses. Med Res Rev doi:10.1002/med.20216.
9. Balzarini J, Van Laethem K, Hatse S, Froeyen M, Peumans W, et al. (2005) Carbohydrate-binding agents cause deletions of highly conserved glycosylation sites in HIV GP120: a new therapeutic concept to hit the achilles heel of HIV. J Biol Chem 280: 41005-41014.
10. Sharon N, Lis H, (2004) History of lectins: from hemagglutinins to biological recognition molecules. Glycobiology 14: 53R-62R.
11. Sharon N, Lis H, (2007) Lectins Dordrecht Springer.
12. Matei E, Zheng A, Furey W, Rose J, Aiken C, et al. (2010) Anti-HIV activity of defective cyanovirin-N mutants is restored by dimerization. J Biol Chem 285: 13057-13065.
13. Moulaei T, Shenoy SR, Giomarelli B, Thomas C, McMahon JB, et al. (2010) Monomerization of viral entry inhibitor griffithsin elucidates the relationship between multivalent binding to carbohydrates and anti-HIV activity. Structure 18: 1104-1115.
14. Takahashi A, Inokoshi J, Tsunoda M, Suzuki K, Takenaka A, et al. (2010) Actinohivin: specific amino acid residues essential for anti-HIV activity. J Antibiot (Tokyo) 63 (11): 661-5.
15. Alexandre KB, Gray ES, Lambson BE, Moore PL, Choge IA, et al. (2010) Mannose-rich glycosylation patterns on HIV-1 subtype C gp120 and sensitivity to the lectins, Griffithsin, Cyanovirin-N and Scytovirin. Virology 402: 187-196.
16. Liu Y, Carroll JR, Holt LA, McMahon J, Giomarelli B, et al. (2009) Multivalent interactions with gp120 are required for the anti-HIV activity of Cyanovirin. Biopolymers 92: 194-200.
17. Tsai CC, Emau P, Jiang Y, Agy MB, Shattock RJ, et al. (2004) Cyanovirin-N inhibits AIDS virus infections in vaginal transmission models. AIDS Res Hum Retroviruses 20: 11-18.
18. Tsai CC, Emau P, Jiang Y, Tian B, Morton WR, et al. (2003) Cyanovirin-N gel as a topical microbicide prevents rectal transmission of SHIV89.6P in macaques. AIDS Res Hum Retroviruses 19: 535-541.
19. Huskens D, Ferir G, Vermeire K, Kehr JC, Balzarini J, et al. (2010) Microvirin, a novel alpha(1,2)-mannose-specific lectin isolated from Microcystis aeruginosa, has anti-HIV-1 activity comparable with that of cyanovirin-N but a much higher safety profile. J Biol Chem 285: 24845-24854.
20. Huskens D, Vermeire K, Vandemeulebroucke E, Balzarini J, Schols D, (2008) Safety concerns for the potential use of cyanovirin-N as a microbicidal anti-HIV agent. Int J Biochem Cell Biol 40: 2802-2814.
21. Balzarini J, Van Laethem K, Peumans WJ, Van Damme EJ, Bolmstedt A, et al. (2006) Mutational pathways, resistance profile, and side effects of cyanovirin relative to human immunodeficiency virus type 1 strains with N-glycan deletions in their gp120 envelopes. J Virol 80: 8411-8421.
22. Buffa V, Stieh D, Mamhood N, Hu Q, Fletcher P, et al. (2009) Cyanovirin-N potently inhibits human immunodeficiency virus type 1 infection in cellular and cervical explant models. J Gen Virol 90: 234-243.
23. O'Keefe BR, Vojdani F, Buffa V, Shattock RJ, Montefiori DC, et al. (2009) Scaleable manufacture of HIV-1 entry inhibitor griffithsin and validation of its safety and efficacy as a topical microbicide component. Proc Natl Acad Sci U S A 106: 6099-6104.
24. Mori T, O'Keefe BR, Sowder RC 2nd, Bringans S, Gardella R, et al. (2005) Isolation and characterization of griffithsin, a novel HIV-inactivating protein, from the red alga Griffithsia sp. J Biol Chem 280: 9345-9353.
25. Emau P, Tian B, O'Keefe BR, Mori T, McMahon JB, et al. (2007) Griffithsin, a potent HIV entry inhibitor, is an excellent candidate for anti-HIV microbicide. J Med Primatol 36: 244-253.
26. Ziolkowska NE, O'Keefe BR, Mori T, Zhu C, Giomarelli B, et al. (2006) Domain-swapped structure of the potent antiviral protein griffithsin and its mode of carbohydrate binding. Structure 14: 1127-1135.
27. Ibanez de Caceres I, Cortes-Sempere M, Moratilla C, Machado-Pinilla R, Rodriguez-Fanjul V, et al. (2010) IGFBP-3 hypermethylation-derived deficiency mediates cisplatin resistance in non-small-cell lung cancer. Oncogene 29: 1681-1690.
28. Smee DF, Bailey KW, Wong MH, O'Keefe BR, Gustafson KR, et al. (2008) Treatment of influenza A (H1N1) virus infections in mice and ferrets with cyanovirin-N. Antiviral Res 80: 266-271.
29. Barrientos LG, O'Keefe BR, Bray M, Sanchez A, Gronenborn AM, et al. (2003) Cyanovirin-N binds to the viral surface glycoprotein, GP1,2 and inhibits infectivity of Ebola virus. Antiviral Res 58: 47-56.
30. O'Keefe BR, Giomarelli B, Barnard DL, Shenoy SR, Chan PK, et al. (2010) Broad-spectrum in vitro activity and in vivo efficacy of the antiviral protein griffithsin against emerging viruses of the family Coronaviridae. J Virol 84: 2511-2521.
31. Barrientos LG, Matei E, Lasala F, Delgado R, Gronenborn AM, (2006) Dissecting carbohydrate-Cyanovirin-N binding by structure-guided mutagenesis: functional implications for viral entry inhibition. Protein Eng Des Sel 19: 525-535.
32. Yang F, Bewley CA, Louis JM, Gustafson KR, Boyd MR, et al. (1999) Crystal structure of cyanovirin-N, a potent HIV-inactivating protein, shows unexpected domain swapping. J Mol Biol 288: 403-412.
33. Roberts JN, Buck CB, Thompson CD, Kines R, Bernardo M, et al. (2007) Genital transmission of HPV in a mouse model is potentiated by nonoxynol-9 and inhibited by carrageenan. Nat Med 13: 857-861.
34. Beer BE, Doncel GF, Krebs FC, Shattock RJ, Fletcher PS, et al. (2006) In vitro preclinical testing of nonoxynol-9 as potential anti-human immunodeficiency virus microbicide: a retrospective analysis of results from five laboratories. Antimicrob Agents Chemother 50: 713-723.
35. Stafford MK, Ward H, Flanagan A, Rosenstein IJ, Taylor-Robinson D, et al. (1998) Safety study of nonoxynol-9 as a vaginal microbicide: evidence of adverse effects. J Acquir Immune Defic Syndr Hum Retrovirol 17: 327-331.
36. Galen BT, Martin AP, Hazrati E, Garin A, Guzman E, et al. (2007) A comprehensive murine model to evaluate topical vaginal microbicides: mucosal inflammation and susceptibility to genital herpes as surrogate markers of safety. J Infect Dis 195: 1332-1339.
37. Marais D, Carrara H, Kay P, Ramjee G, Allan B, et al. (2006) The impact of the use of COL-1492, a nonoxynol-9 vaginal gel, on the presence of cervical human papillomavirus in female sex workers. Virus Res 121: 220-222.
38. Fichorova RN, Rheinwald JG, Anderson DJ, (1997) Generation of papillomavirus-immortalized cell lines from normal human ectocervical, endocervical, and vaginal epithelium that maintain expression of tissue-specific differentiation proteins. Biol Reprod 57: 847-855.
39. Balzarini J, (2006) Inhibition of HIV entry by carbohydrate-binding proteins. Antiviral Res 71: 237-247.
40. Van Damme EJ, Barre A, Verhaert P, Rouge P, Peumans WJ, (1996) Molecular cloning of the mitogenic mannose/maltose-specific rhizome lectin from Calystegia sepium. FEBS Lett 397: 352-356.
41. Sharkey DJ, Macpherson AM, Tremellen KP, Robertson SA, (2007) Seminal plasma differentially regulates inflammatory cytokine gene expression in human cervical and vaginal epithelial cells. Mol Hum Reprod 13: 491-501.
42. Mori T, Gustafson KR, Pannell LK, Shoemaker RH, Wu L, et al. (1998) Recombinant production of cyanovirin-N, a potent human immunodeficiency virus-inactivating protein derived from a cultured cyanobacterium. Protein Expr Purif 12: 151-158.
43. Benjamini Y, Drai D, Elmer G, Kafkafi N, Golani I, (2001) Controlling the false discovery rate in behavior genetics research. Behav Brain Res 125: 279-284.
44. Reiner A, Yekutieli D, Benjamini Y, (2003) Identifying differentially expressed genes using false discovery rate controlling procedures. Bioinformatics 19: 368-375.
45. Breitling R, (2006) Biological microarray interpretation: the rules of engagement. Biochim Biophys Acta 1759: 319-327.
46. Booij JC, ten Brink JB, Swagemakers SM, Verkerk AJ, Essing AH, et al. (2010) A new strategy to identify and annotate human RPE-specific gene expression. PLoS One 5: e9341.
47. Li Z, Liu B, Maminishkis A, Mahesh SP, Yeh S, et al. (2008) Gene expression profiling in autoimmune noninfectious uveitis disease. J Immunol 181: 5147-5157.
48. Livak KJ, Schmittgen TD, (2001) Analysis of relative gene expression data using real-time quantitative PCR and the 2(-Delta Delta C(T)) Method. Methods 25: 402-408.